Dynogen Pharma gets $50M round (TheDeal.com)
News | 04. 19. 2004
Boston-based Dynogen Pharmaceuticals Inc. said Monday, April 19, it had secured a $50 million B round of financing that it will use to further develop its neuroscientific approach to treating genitourinary and gastrointestinal disorders.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.